Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $2.18 Average PT from Analysts

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $2.18.

A number of research firms have issued reports on ADAP. StockNews.com assumed coverage on Adaptimmune Therapeutics in a report on Friday, March 21st. They issued a “buy” rating on the stock. Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research report on Friday, March 21st. Finally, Scotiabank decreased their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st.

Adaptimmune Therapeutics Stock Down 9.7 %

Shares of ADAP stock opened at $0.25 on Friday. The company has a market capitalization of $63.97 million, a price-to-earnings ratio of -1.14 and a beta of 2.52. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The stock’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.68. Adaptimmune Therapeutics has a twelve month low of $0.25 and a twelve month high of $1.65.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The firm had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. As a group, research analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Trading of Adaptimmune Therapeutics

Several large investors have recently added to or reduced their stakes in ADAP. GSA Capital Partners LLP bought a new position in Adaptimmune Therapeutics in the 3rd quarter valued at $95,000. FMR LLC lifted its position in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after buying an additional 50,419 shares in the last quarter. Jane Street Group LLC grew its holdings in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the last quarter. Virtu Financial LLC raised its stake in shares of Adaptimmune Therapeutics by 27.5% in the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 21,769 shares during the last quarter. Finally, LPL Financial LLC raised its position in Adaptimmune Therapeutics by 106.5% in the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 94,623 shares during the last quarter. 31.37% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.